Publication

Video

Supplements and Featured Publications

Targeted Advances in ALK+ NSCLC
Volume1
Issue 1

Dr. Saxena on the Importance of Biomarker Testing in ALK+ NSCLC

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the importance of biomarker testing in stage IV ALK-positive non—small cell lung cancer (NSCLC).

Since the emergence of targeted therapy for patients with ALK-positive NSCLC, biomarker testing has become increasingly relevant, says Saxena. Testing is the only way to determine if patients have an ALK mutation.

Multiple testing options exist including immunohistochemistry, fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, and next-generation sequencing, explains Saxena. Often, testing for an array of mutations with broad panels is done as opposed to testing for individual ALK mutations.

Emerging data suggests a patient’s specific ALK fusion may predict future mutations which could potentially guide treatment selection, concludes Saxena.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity